Atlas Trials

Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer

Clinical trial NCT05255523 · UNKNOWN

Trial details

NCT number
NCT05255523
Sponsor
Fujian Medical University Union Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced Breast Cancer
Start date
2022-02-20
Primary completion
2023-11-05
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.